Eli Lilly Drugstore LLC (Lilly) and the Department of Health – Abu Dhabi (DoH), regulator of the healthcare sector in Abu Dhabi, have signed a Memorandum of Understanding (MoU) to address obesity and Alzheimer’s disease, two of the most pressing health challenges in the region.
Through this landmark collaboration, Lilly and DoH will explore establishing an AI enabled obesity healthcare model and a world-class Alzheimer's Disease Centre of Excellence in Abu Dhabi.
The collaboration combines Lilly’s deep therapeutic expertise and leadership in transformative medicines with Abu Dhabi’s robust population data and advanced healthcare infrastructure, supporting Abu Dhabi’s vision to become a leading global hub for life sciences and innovation. The collaboration will focus on two core strategic workstreams.
First, Lilly and DoH aim to establish a joint task force to co-design and develop an AI-enabled obesity and cardiometabolic care model, tailored to the needs of the Abu Dhabi population. The initiative is expected to leverage Abu Dhabi’s population health data and Lilly’s therapeutic expertise in metabolic diseases to support advanced risk stratification and personalised interventions.
The second workstream aims to focus on exploring advancing the development of an Alzheimer's Disease Centre of Excellence, building on the neurodegenerative disease collaboration between DoH and Lilly, with the aim to strengthen early detection, integrated digital cognitive screening, and care pathways across the Alzheimer's disease continuum.
